<p>/PRNewswire/ -- 罗森律师事务所是一家全球投资者权益律师事务所，宣布代表在 2022 年 10 月 31 日至 2024 年 8 月 2 日（包括这两个日期）期间购买 Actinium Pharmaceuticals, Inc.（纽约证券交易所代码：ATNM）证券的投资者提起集体诉讼（“集体诉讼期间”）。已经提起了集体诉讼。如果您希望担任首席原告，必须在 2025 年 5 月 26 日之前向法院提出申请。</p>
<p>那么，您在集体诉讼期间购买了 Actinium 证券，可能有权获得赔偿，而无需支付任何自掏腰包的费用或成本，采用风险代理费用安排。</p>
<p>接下来该怎么做：要加入 Actinium 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=37511 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。已经提起了集体诉讼。如果您希望担任首席原告，必须在 2025 年 5 月 26 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
<p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的律师事务所没有可比的经验、资源或任何有意义的同行认可。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾在当时获得针对一家中国公司的最大证券集体诉讼和解。2017 年，罗森律师事务所被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一名。自 2013 年以来，该事务所每年都排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
<p>案件详情：根据诉讼，集体诉讼期间，被告作出了虚假和/或误导性的陈述，和/或未能披露以下内容：（1）Actinium 的 Sierra 试验数据不太可能满足美国食品和药物管理局（“FDA”）对 Actinium 的 Iomab-B 生物制品许可申请（“BLA”）的接受和批准的指导方针；（2）包括长期跟踪在内的额外分析，声称展示了改善总体生存率（“OS”）的趋势，Actinium 向 FDA 提供的这些数据试图减轻 Sierra 试验的糟糕 OS 数据，但不太可能满足 FDA 对 Actinium 的 Iomab-B BLA 的接受和批准的指导方针；（3）因此，FDA 可能会拒绝审查 Iomab-B BLA，或者如果考虑该 BLA，该申请在当前形式下不太可能获得批准；（4）因此，被告对 Actinium 的业务、运营和前景的积极陈述在实质上具有误导性，和/或缺乏合理依据。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
<p>要加入 Actinium 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=37511 https://rosenlegal.com/submit-form/?case_id=28116 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
<p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择您自己的律师。您也可以选择保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
<p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm 或在 Twitter 上：https://twitter.com/rosen_firm 或在 Facebook 上：https://www.facebook.com/rosenlawfirm。</p>
<p>律师广告。之前的结果并不保证类似的结果。</p>
<p>联系信息：</p>
<p>Laurence Rosen, Esq.</p>
<p>Phillip Kim, Esq.</p>
<p>罗森律师事务所，P.A.</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>纽约， NY 10016</p>
<p>电话: (212) 686-1060</p>
<p>免费电话: (866) 767-3653</p>
<p>传真: (212) 202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>来源：罗森律师事务所，P.A.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzI5Jk5ld3NJdGVtSWQ9REM1MzAyMSZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMjkxMzE1UFJfTkVXU19VU1BSX19fX19EQzUzMDIx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzI5Jk5ld3NJdGVtSWQ9REM1MzAyMSZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMjkxMzE1UFJfTkVXU19VU1BSX19fX19EQzUzMDIx"/></p>

Actinium制药

<p>罗森律师事务所代表 Actinium Pharmaceuticals, Inc.（纽约证券交易所美国：ATNM）的投资者提起了集体诉讼，指控其在 2022 年 10 月 31 日至 2024 年 8 月 2 日期间存在证券欺诈。投资者可能有权获得赔偿，无需预付费用。诉讼指控 Actinium 在其 Iomab-B 生物制品许可证申请中做出了误导性陈述，该申请可能不符合 FDA 的指导方针。有兴趣的投资者可以在 2025 年 5 月 26 日之前联系该事务所加入集体诉讼</p>

<p>, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024, both dates inclusive (the &#34;Class Period&#34;). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2025.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 罗森律师事务所是一家全球投资者权益律师事务所，宣布代表在 2022 年 10 月 31 日至 2024 年 8 月 2 日（包括这两个日期）期间购买 Actinium Pharmaceuticals, Inc.（纽约证券交易所代码：ATNM）证券的投资者提起集体诉讼（“集体诉讼期间”）。已经提起了集体诉讼。如果您希望担任首席原告，必须在 2025 年 5 月 26 日之前向法院提出申请。</p>
</div><p>So What: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那么，您在集体诉讼期间购买了 Actinium 证券，可能有权获得赔偿，而无需支付任何自掏腰包的费用或成本，采用风险代理费用安排。</p>
</div><p>What to do next: To join the Actinium class action, go to https://rosenlegal.com/submit-form/?case_id=37511 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下来该怎么做：要加入 Actinium 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=37511 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。已经提起了集体诉讼。如果您希望担任首席原告，必须在 2025 年 5 月 26 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的律师事务所没有可比的经验、资源或任何有意义的同行认可。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾在当时获得针对一家中国公司的最大证券集体诉讼和解。2017 年，罗森律师事务所被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一名。自 2013 年以来，该事务所每年都排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
</div><p>Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Actinium's data from Sierra Trial was unlikely to satisfy the U.S. Food and Drug Administration's (&#34;FDA&#34;) guidelines for the acceptance and approval of Actinium's Iomab-B Biologics License Application (&#34;BLA&#34;); (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival (&#34;OS&#34;) that Actinium provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Actinium's Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4) as a result, defendants' positive statements about Actinium's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>案件详情：根据诉讼，集体诉讼期间，被告作出了虚假和/或误导性的陈述，和/或未能披露以下内容：（1）Actinium 的 Sierra 试验数据不太可能满足美国食品和药物管理局（“FDA”）对 Actinium 的 Iomab-B 生物制品许可申请（“BLA”）的接受和批准的指导方针；（2）包括长期跟踪在内的额外分析，声称展示了改善总体生存率（“OS”）的趋势，Actinium 向 FDA 提供的这些数据试图减轻 Sierra 试验的糟糕 OS 数据，但不太可能满足 FDA 对 Actinium 的 Iomab-B BLA 的接受和批准的指导方针；（3）因此，FDA 可能会拒绝审查 Iomab-B BLA，或者如果考虑该 BLA，该申请在当前形式下不太可能获得批准；（4）因此，被告对 Actinium 的业务、运营和前景的积极陈述在实质上具有误导性，和/或缺乏合理依据。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
</div><p>To join the Actinium class action, go to https://rosenlegal.com/submit-form/?case_id=37511 https://rosenlegal.com/submit-form/?case_id=28116call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 Actinium 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=37511 https://rosenlegal.com/submit-form/?case_id=28116 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择您自己的律师。您也可以选择保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.</p>
<div class="lb-trans"><p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm 或在 Twitter 上：https://twitter.com/rosen_firm 或在 Facebook 上：https://www.facebook.com/rosenlawfirm。</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。之前的结果并不保证类似的结果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>联系信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen, Esq.</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim, Esq.</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>罗森律师事务所，P.A.</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>纽约， NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>电话: (212) 686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免费电话: (866) 767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>传真: (212) 202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>来源：罗森律师事务所，P.A.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzI5Jk5ld3NJdGVtSWQ9REM1MzAyMSZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMjkxMzE1UFJfTkVXU19VU1BSX19fX19EQzUzMDIx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC53021&amp;Transmission_Id=202503291315PR_NEWS_USPR_____DC53021&amp;DateId=20250329"/></p>

13:15 ET
			
			
				ATNM Investors Have Opportunity to Lead ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit

ATNM 投资者有机会领导 ROSEN，这是一家全国知名的投资者顾问公司，鼓励对 Actinium 制药公司的证券欺诈提起诉讼